INSIAS (In Silico Assessments) is committed to support pharmaceutical and biotech, as well as medical device companies in the qualification of their product related impurities whilst avoiding animal testing, whenever feasible.
When no adequate experimental mutagenicity and/or carcinogenicity results are available, a structure-based computational toxicology or (Q)SAR analysis may be used to predict the mutagenic potential of an impurity. (Q)SAR models are also available for other endpoints such as, but not limited to, irritation and sensitization.
Company Details
- Employees
- 2
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Keywords
- IT Consulting.
- Competitors
- ICC.
Insias Questions
Insias's LinkedIn profile is https://www.linkedin.com/company/insias
Insias has
2 employees.
View email and phone details for 2
employees at Insias.
Insias's industry is
Pharmaceutical Manufacturing
Insias's top competitors are
Icc.
Insias's categories are Pharmaceutical Manufacturing
